Document text
Principal Investigator: Lanying Du
Organization: GEORGIA STATE UNIVERSITY
Fiscal Year: 2022
Award: $759,731
Funding agency: National Institute of Allergy and Infectious Diseases
Summary
A novel coronavirus (CoV), SARS-CoV-2, is causing global pandemics with growing numbers of daily cases
and deaths. SARS-CoV-2 is closely related to SARS-CoV, which caused the 2002-2003 SARS epidemic, and
less closely related to MERS-CoV, which causes a high mortality rate in infected patients. No therapeutic
agents or vaccines have been approved to control the infections of these CoVs in humans, calling for
immediate efforts to develop effective countermeasures. The CoV spike (S) proteins are important targets for
therapeutics. They guide virus entry into host cells by binding to a host receptor through their S1 subunits and
fusing the viral and host cell membranes through their S2 subunits. The S1 subunits contain a receptor-binding
domain (RBD). Both RBD and S2 region of S protein can elicit neutralizing antibodies. The RBD is the major
target to induce potent neutralizing antibodies, but it diverges among different CoVs, whereas the S2 region of
S protein is more conserved among different CoVs. Nanobodies (Nbs) are single-domain antibodies derived
from camelid antibodies. They are emerging as novel therapeutic agents, numbers of which have been
approved or tested in clinical trials to prevent and treat other human diseases. Nbs possess many unique
advantages as therapeutic agents: they have high physical and chemical stabilities, excellent tissue
penetration capability (superior pharmacokinetics), easy expression with great production yields, and
robustness for storage and transportation. Moreover, Nbs can potentially recognize epitopes (e.g. hidden or
partially hidden epitopes) that are not accessible to conventional antibodies. In this proposal, we will design
and develop Nbs as therapeutic agents against SARS-CoV-2 and other pathogenic human CoVs using phage
display and structural biology as guiding tools. We propose to develop highly efficacious Nbs against SARS-
CoV-2 to stop the current COVID-19 pandemic and also broad-spectrum neutralizing Nbs targeting future CoV
infections. We have established Nb libraries and identified several neutralizing Nbs targeting the RBDs of
SARS-CoV and MERS-CoV, providing a solid foundation for the proposed studies. In our previous work, we
extensively characterized the structures and functions of MERS-CoV and SARS-CoV S proteins, and we have
recently characterized the RBD of SARS-CoV-2 and solved its structure in complex with viral receptor, paving
the way for rapid screening and identification of SARS-CoV-2 S protein-based Nbs. The specific aims of this
proposal are to: 1) develop highly efficacious Nbs targeting SARS-CoV-2 S (RBD/S2) protein; develop broad-
spectrum Nbs against CoV infections, 2) characterize these CoV S-targeting Nbs, and 3) evaluate in vivo
efficacy of these Nbs against SARS-CoV-2 and other CoV infections. Overall, this proposal will develop
highly efficacious Nbs targeting SARS-CoV-2 S protein, aiming to stop the current COVID-19 pandemic. It will
also develop broad-spectrum Nbs targeting future CoV infections. This proposal has important implications for
combating pathogenic coronaviruses and neutralizing their threat to human health.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><Affinity><Animal Model><Animal Models and Related Studies><Antibodies><Antigenic Determinants><Antigens><Binding><Binding Determinants><Body Tissues><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 therapeutics><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 therapeutics><COVID19 virus><CV-19><CV19><Cancers><Cell Body><Cell Culture Techniques><Cell membrane><Cells><Cessation of life><Clinical Trials><CoV S protein><CoV emergence><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><CoV-2><CoV2><Complex><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Coronavirus glycoprotein S><Coronavirus spike protein><Cryo-electron Microscopy><Cryoelectron Microscopy><Cytoplasmic Membrane><Death><Development><Dipeptidyl Aminopeptidases><Dipeptidyl Peptidases><Dipeptidylpeptide Hydrolases><Drug Kinetics><Drug or chemical Tissue Distribution><Electron Cryomicroscopy><Electrons><Engineering><Epidemic><Epitopes><Evaluation><Foundations><Future><Goals><Guidelines><HCoV><Half-Life><Health><Human><Infection Control><Libraries><Life><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Malignant Neoplasms><Malignant Tumor><Membrane><Microscopic><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><Negative Beta Particle><Negatrons><Pathogenesis><Pathogenicity><Patients><Penetration><Phage Display><Pharmacokinetics><Phase><Plasma Membrane><Position><Positioning Attribute><Production><Proteins><Rapid screening><Receptor Protein><Research><Roentgen Rays><SARS><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV disease><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Solid><Solubility><Structure><Surface><Techniques><Testing><Therapeutic><Therapeutic Agents><Tissue Distribution><Tissues><Toxic effect><Toxicities><Transportation><Treatment Efficacy><Vaccine Design><Viral><Viral Diseases><Viral Receptor><Virus><Virus Diseases><Virus Receptors><Work><Wuhan coronavirus><X-Radiation><X-Ray Radiation><X-ray><Xray><angiotensin converting enzyme 2><angiotensin converting enzyme II><base><candidate selection><cell culture><cell cultures><chemical stability><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus emergence><coronavirus S protein><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus of pandemic concern><coronavirus of pandemic potential><coronavirus spike glycoprotein><coronavirus with pandemic potential><cryo-EM><cryoEM><design><designing><developmental><effective therapy><effective treatment><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><global health><hCoV19><human CoV><human corona virus><human coronavirus><human disease><immunogen><in vivo><in vivo evaluation><in vivo testing><intervention efficacy><malignancy><membrane structure><model of animal><model organism><mortality><mouse model><murine model><nCoV><nCoV2><nanobodies><nanobody><neoplasm/cancer><neutralizing antibody><new CoV><new corona virus><new coronavirus><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><non-human primate><nonhuman primate><novel><novel CoV><novel corona virus><novel coronavirus><novel drug treatments><novel drugs><novel therapeutics><novel therapy><pandemic><pandemic coronavirus><pandemic disease><pandemic threat coronavirus><pathogenic virus><plasmalemma><prevent><preventing><prophylactic><receptor><receptor binding><receptor bound><screening><sdAb><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome-CoV><single domain antibodies><structural biology><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapeutic vaccine><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><therapy efficacy><tool><treatment vaccines><vaccine for the treatment><vaccine for treatment><viral infection><viral pathogen><virus infection><virus pathogen><virus-induced disease>